Actively Recruiting
Pilot Study to Assess Safety of ExOlin Device and Insulin Treatment in Adults with Poorly Controlled Type 1 Diabetes and High Blood Sugar Fluctuations
Led by Defymed · Updated on 2022-07-27
8
Participants Needed
1
Research Sites
17 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety of ExOlin, a device combined with insulin aspart, in adults with poorly controlled Type 1 Diabetes who experience high blood sugar fluctuations and are prone to severe hypoglycemia. This pilot study is open-label and conducted at a single center. It aims to observe how patients respond to the device and drug combination over an extended period, focusing on any adverse events related to the treatment. Participants will undergo a screening phase followed by implantation of the ExOlin device. They will then use the device to receive insulin aspart during the treatment phase. After this period, the device will be removed, and patients will be monitored in a post-explantation safety follow-up. The study includes mandatory phases lasting 32 weeks from device implantation and an optional extension phase lasting up to 168 weeks for some participants. Throughout the trial, patients will be closely monitored for safety, including the occurrence of adverse events related to the device or treatment. Researchers will also assess glycemic control at various points during the study and evaluate quality of life using a diabetes-specific questionnaire. Monitoring includes vital signs, physical exams, and regular check-ins throughout the treatment and follow-up periods, with total participation lasting up to several years depending on extension phase involvement.
CONDITIONS
Brief Title
Pilot Study Evaluating Safety of ExOlin® in Patients With Poorly Controlled Type 1 Diabetes
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here